Earlier Recognition: Screening, Biomarkers, and Digital Assessment

Primary-care tools such as MyCog may support earlier cognitive-impairment recognition, while speech, retinal, and remote assessment research suggests possible scalable signals. Accuracy, accessibility, privacy, implementation, and outcome evidence remain incomplete. Blood biomarkers including p-tau217 should support—not replace—a stepped clinical evaluation and are not established for healthy-person screening or standalone diagnosis.